Welcome to our dedicated page for Viemed Healthcare news (Ticker: VMD), a resource for investors and traders seeking the latest updates and insights on Viemed Healthcare stock.
Viemed Healthcare, Inc. provides technology-enabled, home-based healthcare solutions and chronic disease management in the United States. Company news centers on home medical equipment and post-acute healthcare services, including respiratory care, non-invasive ventilation, sleep and resupply offerings, oxygen therapy, chronic care, and women's health products and services delivered with clinical support in the home.
Recurring updates include quarterly and annual financial results, guidance, revenue mix, patient-start trends, capital expenditure expectations, share repurchase activity, investor presentations, and analyst coverage. Viemed's releases also discuss service-line diversification, medical equipment rental, sales and supply revenue, reimbursement and coverage documentation dynamics, and the contribution of its 2025 acquisition of Lehan's Medical Equipment.
Stonegate Capital Partners updated coverage on Viemed Healthcare (NASDAQ: VMD) following 1Q26. The firm highlights stronger free cash flow (FCF) conversion, shifting revenue mix toward sleep, resupply, maternal health, and commercial payors, while legacy ventilation navigates the NCD transition but still faces turnover-related census pressure.
Key metrics include higher CFFO and TTM FCF, lower ventilator rental mix, and rapid PAP and resupply patient growth.
Viemed (NASDAQ:VMD) reported Q1 2026 results for the quarter ended March 31, 2026. Net revenue was $75.4 million, up 28% year‑over‑year. Net income attributable totaled $2.6 million, and Adjusted EBITDA was $14.3 million, a 12% increase.
The company repurchased 150,000 shares for $1.4 million, held $9.8 million in cash, and updated full‑year 2026 guidance: net revenue $312–$320M, Adjusted EBITDA $65–$69M, and net capex 9%–10.5% of revenue.
Viemed Healthcare (NASDAQ:VMD) will host its First Quarter 2026 earnings conference call on Wednesday, May 6, 2026 at 11:00 a.m. EDT. Interested parties may dial provided numbers or listen via live webcast; a replay will be posted in the Investor Relations section at www.viemed.com.
Viemed Healthcare (NASDAQ:VMD) will present and host one-on-one investor meetings at Sidoti's Small-Cap Virtual Investor Conference on March 18-19, 2026. The company presentation is scheduled for 1:45 p.m. ET on March 19, 2026. Registration is free and open online.
Investors can access the live presentation via Sidoti's webinar link and sign up for virtual one-on-ones on March 18-19, 2026.
Viemed Healthcare (NASDAQ: VMD) reported FY25 results showing net revenue of $270.3M (up 21% y/y), net income $14.9M, and record adjusted EBITDA $61.4M. Free cash flow rose 141% y/y. Growth was driven by platform momentum, contributions from Lehan's, and stronger sleep/resupply adoption. A revised NCD added documentation and tightened coverage criteria, temporarily moderating ventilator patient growth, though reimbursement levels were unchanged and vent activity began normalizing. Management and coverage updates indicate sleep and resupply are improving recurring revenue quality and diversification of payors, while FY26 guidance and valuation suggest upside may be underappreciated.
Viemed Healthcare (NASDAQ:VMD) announced a share repurchase program effective through March 2027 authorizing purchases of up to 1,930,131 common shares, about 5% of issued shares as of March 4, 2026. Purchases may occur via open market or block trades and repurchased shares will be cancelled.
The company highlighted prior repurchases of ~4.5 million shares totaling $26.3 million, record 2025 revenue and Adjusted EBITDA, more than doubled free cash flow year-over-year, $13.5 million cash at year-end, and effectively no net debt.
Viemed Healthcare (NASDAQ:VMD) reported record 2025 results and issued 2026 guidance on March 4, 2026. Q4 net revenue was $76.2M (+26% YoY) and FY revenue was $270.3M (+21% YoY). FY net income was $14.9M ($0.37/diluted), Adjusted EBITDA a record $61.4M.
The company generated $51.9M cash from operations and $28.1M free cash flow in 2025, maintained $13.5M cash and $7.4M working capital, and had $46M available on its credit facility. 2026 guidance: revenue $310–320M, Adjusted EBITDA $65–69M, capex 10–11.5% of revenue. Board authorized a 2026 share repurchase program.
Viemed Healthcare (NASDAQ:VMD) will host its Year End 2025 earnings conference call on Thursday, March 5, 2026 at 11:00 a.m. ET. Interested parties may dial US Toll-Free or international numbers or join via live audio webcast.
A replay will be available in the Investor Relations section of the company website at www.viemed.com after the live call.
Stonegate Capital Partners initiated coverage on Viemed Healthcare (NASDAQ: VMD) on January 6, 2026.
Viemed is described as a leading U.S. provider of in-home post-acute respiratory care focused on non-invasive ventilation (NIV) for COPD and chronic respiratory failure, operating a clinician-driven model with respiratory therapists, proprietary workflows, and continuous monitoring.
Key disclosed metrics include 15 consecutive quarters of organic growth and management guidance implying approximately 20% year-over-year revenue growth and about 22% EBITDA margins. The firm has diversified into sleep therapy and resupply, oxygen therapy, staffing, and maternity care to broaden its platform.
Viemed Healthcare (NASDAQ:VMD) reported third quarter 2025 results for the three and nine months ended September 30, 2025. Q3 net revenue reached a company record of $71.9M, up 24.0% year-over-year. Net income for Q3 was $3.5M or $0.09 per diluted share. Adjusted EBITDA totaled $16.1M, a 15.5% increase versus prior year.
Cash flow: operating cash flow was $18.4M for the quarter and $48.5M TTM; free cash flow was $12.4M for the quarter and $23.3M TTM.
Corporate actions: closed acquisition of Lehan's Medical Equipment on July 1, 2025; repurchased 1,706,380 shares for $11.4M. Balance sheet: cash $11.1M, working capital $5.8M, long-term debt $19.6M. 2025 guidance updated to $271M–$273M revenue and $60M–$62M adjusted EBITDA.